Online ISSN: 2515-8260

Keywords : NAFLD


A CROSS SECTIONAL ANALYTICAL STUDY TO EVALUATE THE PREVALENCE AND EARLY DIAGNOSIS OF NAFLD IN VARIOUS COMORBIDITIES USING LIPID PROFILE AND HEPATIC ENZYMES AS BIOMARKERS

Chiluka Kiran, Sanath Kumar, Bandi Suman

European Journal of Molecular & Clinical Medicine, 2022, Volume 9, Issue 4, Pages 3058-3066

Background: Nonalcoholic fatty liver disease (NAFLD) is a global epidemic that is often asymptomatic and silent, and progresses slowly and is one of the most common causes of chronic liver disease. NAFLD affects a third of the world population with very much high prevalence among patients with diabetes mellitus, obesity, hypertension, dyslipidemia, hypothyroidism etc. The natural history of NAFLD ranges from pure steatosis to steatohepatitis (NASH) to cirrhosis and in some patientsto hepatocellular carcinoma (HCC). NAFLD has been found to be the hepatic components of metabolic syndrome which is one of the leading causes of chronic liver disease. This study aimed to determine the biochemical hepatic markers and lipid profile among NAFLD patients and their possible relationship with degrees of fatty liver and other comorbidities to aid the clinician tointervene early in order to delay the occurrence of complications associated with NAFLD.
Materials and Methods: In this analytical cross sectional study, 145 individuals aged 20–69 years referred to the Govt Medical College/ GGH Hospital Suryapet during the period from June 2021 to May 2022, were included through sequential sampling method after meeting inclusion and exclusion criteria and after taking informed consent and ethical committee approval. Serum lipid profile and Serum liver enzymes was estimated on ERBA EM 360 auto analyzer.
Results: We found significant increase in lipid parameters (TC, LDL-C, VLDL-C, and TG), liver enzymes (AST, ALT, and GGT) and decrease in HDL-C and AST/ALT (Deritis ratio) in NAFLD with type 2 DM compared to controls.
Conclusion: We conclude from our study that in obesity, dyslipidemia, hypertension, hypothyroidism and Type 2 DM the elevated liver enzymes and lipid profile could be biomarkers for the early diagnosis of NAFLD with Type 2 DM and other comorbidities.

Micro and Macro vascular complications in type 2 diabetic patients with non-alcoholic fatty liver disease

Dr.Anil Kumar, Dr.J Nagajyothi, Dr.Raghu Nandan

European Journal of Molecular & Clinical Medicine, 2022, Volume 9, Issue 1, Pages 447-453

NAFLD is a spectrum of liver lesions ranging from simple hepatic steatosis to NASH with progressive fibrosis leading to cirrhosis and liver failure in some patients and eventually hepatocellular carcinoma. The different parts of this spectrum are probably best regarded as parts of a histological continuum. All patients underwent ultrasound (USG) of the abdomen to detect fatty changes in the liver, performed by aexperienced radiologist, using a high-resolution B-mode ultrasonography system, having an electric linear transducer mid frequency of 3-5 MHz.The scanning was done for an average of 20 minutes.
In our study out of 50 patients,22(44%) patients were having diabetic neuropathy on the basis of clinical examination,out of them 10 (45.45%) patients were males & 12 (54.54%) patients were females. There was higher prevalence of diabetic neuropathy in female patients. 28 (56%) patients were negative for neuropathy. Out of total 50 diabetic patients with NAFLD, 31 (62%) patients were having evidence of CAD, out of 31 patients, 17 (54.8%) were male & 14 (45.2%) were female. 19 (38%) patients having no evidence of CAD.

Pathogenesis, diagnosis, complications and treatment of non-alcoholic fatty liver disease

Ms.Sophy, Dr. Anand Thirupathi

European Journal of Molecular & Clinical Medicine, 2021, Volume 8, Issue 4, Pages 3515-3528

Number of non-alcoholic fatty liver disease (NAFLD) cases is increasing over time due to alteration of food habit, increase incidence of metabolic syndrome, and lack of exercise. Liver biopsy is the test for diagnosis and staging of NAFLD, but nowadays several biochemical markers, scoring systems, and imaging studies are available to diagnose and stage NAFLD which is linked to end-stage liver disease, hepatocellular cancer, and elevated cardiovascular- and cancer-related morbidity and mortality. Therefore urgent diagnosis and management are required to avoid complications related to NAFLD. This study summarizes the latest evidence on the epidemiology, natural history, pathogenesis, diagnosis and management of NAFLD.